- Drakesmith Group: Iron and Immunity Research Group
I work as a research assistant in Hal Drakesmith's group where I primarily consider hepcidin, the iron regulatory hormone, from a global health perspective. We have explored its potential for use as a diagnostic of iron deficiency in a number of environmentally and physiologically different populations. I also contribute to work within the Drakesmith lab that investigates hepcidin and iron status in the context of inflammation and infection.
I addition to this, I have supported the work of Dr Noémi Roy in her development of the Oxford Red Cell Panel, a diagnostic sequencing service within the John Radcliffe that screens for mutations linked to rare congenital anaemias. I continue to work in this area through exploration of potentially disease-causing variants that have been identified by whole genome sequencing.
I hold an MBioch from Oxford University, graduating in 2012 following a research project relating to localisation of mRNA in the neurons of fruit flies, and began work in the Drakesmith lab in 2014.
Serum hepcidin potentially identifies iron deficiency in survivors of critical illness at the time of hospital discharge.
Shah A. et al, (2018), Br J Haematol
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.
Pasricha S-R. et al, (2017), Nat Commun, 8
Hepcidin detects iron deficiency in Sri Lankan adolescents with a high burden of hemoglobinopathy: A diagnostic test accuracy study.
Wray K. et al, (2017), Am J Hematol, 92, 196 - 203
A novel 33-Gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias.
Roy NBA. et al, (2016), Br J Haematol, 175, 318 - 330
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
Jones E. et al, (2015), Blood, 125, 873 - 880